RBC Pore Filterability Before and After HU Treatment
| . | MPD . | MPD + HU . | Controls . |
|---|---|---|---|
| RBCiv 3-μm (nL) | 5.49 ± 1.37 | 16.10 ± 2.982 | 5.11 ± 0.57 |
| RBCcr 3-μm (—) | 31.9 ± 4.3 | 37.6 ± 2.7 | 34.1 ± 2.8 |
| RBCiv 5-μm (nL) | 0.857 ± 0.124 | 1.019 ± 0.148 | 0.691 ± 0.052 |
| RBCcr5-μm (—) | 2.51 ± 0.41 | 1.61 ± 0.44 | 1.58 ± 0.24 |
| . | MPD . | MPD + HU . | Controls . |
|---|---|---|---|
| RBCiv 3-μm (nL) | 5.49 ± 1.37 | 16.10 ± 2.982 | 5.11 ± 0.57 |
| RBCcr 3-μm (—) | 31.9 ± 4.3 | 37.6 ± 2.7 | 34.1 ± 2.8 |
| RBCiv 5-μm (nL) | 0.857 ± 0.124 | 1.019 ± 0.148 | 0.691 ± 0.052 |
| RBCcr5-μm (—) | 2.51 ± 0.41 | 1.61 ± 0.44 | 1.58 ± 0.24 |
Patients with newly diagnosed MPD were analyzed before and after treatment with HU (n = 5). Healthy controls were studied in parallel (n = 5 + 5). Whole blood was centrifuged and washed three times with removal of plasma and white blood cells. The RBCs were resuspended in balanced KRH medium to 5% hematocrit. The RBC filterability was tested through both 3-μm and 5-μm Nucleopore membranes at 600 Pa constant pressure. From the measurements of initial filtration rate and clogging slope as a function of filtration time, the RBC incremental volume (RBCiv) and the RBC clogging rate (RBCcr) were calculated (see the Materials and Methods). Five levels of significances were tested: P < .051, P < .022, P < .013, P < .0054, and P < .0015. No significant differences were found between patients with MPD before treatment and controls.